Scientists from Queen Mary University of London have received a grant from leading men’s health charity, Prostate Cancer UK, as London continues to lead the way in advanced prostate cancer research.
Scientists from Queen Mary University of London have received a grant from leading men’s health charity, Prostate Cancer UK, as London continues to lead the way in advanced prostate cancer research.
Six separate grants worth over £2.5 million have been awarded in London as part of the charity’s Research Innovation Awards scheme which funds forward thinking, ambitious research proposals from across the UK which challenge the status quo.
Dr Gunnel Hallden is leading one of the pioneering studies at Queen Mary. It builds on previous work funded by Prostate Cancer UK, which saw Dr Hallden develop a modified type of flu virus that specifically infects and kills cancer cells, leaving non-cancer cells unharmed.
Dr Hallden from Queen Mary University of London, said: “Our first study proved very successful when the virus was injected directly into cancer cells in mice and used alongside standard chemotherapy drugs. However, we wanted to find a way of delivering it via the blood, so it can reach all tumours in the body at once, instead of being injected into just one.
“This has proven difficult in the past, but by ‘packaging’ the virus with special proteins to help protect it as it travels through the blood, we hope the virus can survive long enough to reach the tumours. We’ll also modify the virus to give it the ability to alert the patient’s immune system to prostate cancer so the patient’s own body will continue to fight the disease.
“Thanks to Prostate Cancer UK’s generous grants, we hope we can soon have a new treatment for men with incurable prostate cancer which will improve both the length and quality of their life.”
Prostate cancer is the most common cancer in men and the disease kills one man every 45 minutes in the UK, amounting to more than 11,500 men every year.
Dr Matthew Hobbs, Director of Research at Prostate Cancer UK said: “Prostate cancer is on target to become the UK’s most commonly diagnosed cancer by 2030, and every year over 9,000 men are diagnosed with prostate cancer too late and told that it can’t be cured.
“That’s why we’re funding innovative research like this to benefit men diagnosed with a later stage of the disease. By funding these six hugely exciting research projects at three different London institutions we believe that London will become an even more effective hub for research that will help to tame prostate cancer.
“Prostate Cancer UK is determined to tame this disease and we have the focus and expertise that will enable us to achieve that aim. However, funding the best research like these six projects requires funds. That’s why we’re encouraging everyone to sign up to the London March for Men – one in our series of mass participation walking events taking place across the UK this summer. The London march alone has raised an incredible half a million pounds over the last two years to help fund vital research, and we’d like to ask you to pull your boots on again for an even bigger, even better March for Men in 2019.”
In a bid to ramp up its fundraising Prostate Cancer UK launched three March for Men walks, in 2017, to help raise the vital funds needed for research.
Two years on, Prostate Cancer UK’s March for Men series includes walks in London, Manchester, Nottingham, Bristol, Leeds, Liverpool and Glasgow – with more to be announced soon. So far, 6,300 walkers have raised over £825,000 in funds to stop prostate cancer being a killer.
###
To register your interest in a March for Men event in 2019, visit: prostatecanceruk.org/march
For further information on research funded by Prostate Cancer UK visit:
https:/
For more information, please contact:
Joel Winston
Public Relations Manager (School of Medicine and Dentistry)
Queen Mary University of London
[email protected]
Tel: +44 (0)20 7882 7943 / +44 (0)7970 096 188
Notes to the editor
About Queen Mary University of London
Queen Mary University of London is a world-leading research-intensive university with over 25,000 students representing more than 160 nationalities.
A member of the prestigious Russell Group, we work across the humanities and social sciences, medicine and dentistry, and science and engineering, with inspirational teaching directly informed by our research.
In the most recent exercise that rated research in the UK, we were ranked 5th in the country for the proportion of research outputs that were world-leading or internationally excellent. We offer more than 240 degree programmes and our reputation for excellent teaching was rewarded with a silver in the 2017 Teaching Excellence Framework (TEF) awards.
Queen Mary’s history dates back to 1785, with the foundation of the London Hospital Medical College. Our history also encompasses the establishment of the People’s Palace in 1887, which brought accessible education, culture and recreation to the East End of London. We also have roots in Westfield College, one of the first colleges to provide higher education to women.
About Prostate Cancer UK
- o Prostate Cancer UK has a simple ambition – to stop men dying from prostate cancer.
o As the number of men diagnosed with prostate cancer continues to rise (making it the most common of all cancers by 2030), now is the time to take control. Through shifting the science over the next 10 years to focus on radical improvements in diagnosis, treatment, prevention, and support, we will stop prostate cancer being a killer.
o Ignoring prostate cancer won’t beat it, so join the fight.
Key Headline Statistics
- o More than 11,500 men die from prostate cancer in the UK each year – that’s one man every 45 minutes.
o It’s the most common cancer in men, with over 400,000 living with and after the disease in the UK.
o Prostate cancer is set to become the most commonly diagnosed cancer of all in the UK by 2030 – which is why we must all act now to curb its power to kill.
o Men over 50, black men and men with a family history of prostate cancer all face a higher than average risk of the disease.
o Prostate cancer treatment often causes devastating, long term side-effects. Incontinence and erectile dysfunction strike at the heart of what it means to be a man.
o Anyone with concerns about prostate cancer may contact Prostate Cancer UK’s Specialist Nurses in confidence on 0800 074 8383 or online via the Live Chat instant messaging service: http://www.
o Visit prostatecanceruk.org now to help beat this disease.
Media Contact
Joel Winston
[email protected]
44-020-788-27943
